MHC-II expression was observed in > 1% of melanoma cells in 55/181 (30%) patients, and correlated with IFN-γ and its mediated gene signature, which could predict the response to anti-PD-1 but not anti-CTLA-4 therapy [152]. The gene discussed is IFNG; the disease is melanoma.